RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
20 mars 2024 08h30 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), focused on the discovery and development of innovative and...
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
01 mars 2024 16h04 HE
|
NurExone Biologic Inc
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
Climate Change Challenge Creates Solutions for Vulnerable Populations
20 févr. 2024 15h57 HE
|
Praxis Spinal Cord Institute
Vancouver, BC, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Praxis Spinal Cord Institute NEWS RELEASEFor Immediate Release February 20, 2024 Climate Change Challenge Creates Solutions for Vulnerable...
Wandercraft's self-balancing exoskeleton receives second FDA clearance in less than a year, now indicated for rehabilitation in patients with spinal cord injury
13 févr. 2024 08h05 HE
|
Wandercraft
Wandercraft's self-balancing exoskeleton receives second FDA clearance in less than a year, now indicated for rehabilitation in patients with spinal cord injury This marks Wandercraft’s second FDA...
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
02 févr. 2024 16h05 HE
|
NurExone Biologic Inc
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product
NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration
29 nov. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone Biologic expands its portfolio of products to address spinal cord injuries & neuron regeneration in CNS indications
NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update
24 nov. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone released a corporate update and reported financial results for the quarter ended September 30, 2023.
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
30 oct. 2023 09h20 HE
|
NurExone Biologic Inc
NurExone Biologic Receive FDA Orphan-Drug Designation to its ExoPTEN Therapy for Acute Spinal Cord Injury Treatment
Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee
19 oct. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone Biologic welcomes Prof. Teodoro Forcht Dagi, a renowned neurosurgeon and life science venture capitalist, to its Scientific Advisory Board.
ONWARD® kondigt aan dat ARC-IM™ stimulator met Brein-Computer Interface (BCI) voor het eerst bij mensen wordt geïmplanteerd om de functie van armen, handen en vingers na ruggenmergletsel te herstellen
27 sept. 2023 01h30 HE
|
ONWARD Medical NV
Eindhoven, Sept. 27, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), het medische technologiebedrijf dat innovatieve ruggenmergstimulatietherapieën ontwikkelt om beweging, functie en...